Mealey's (May 28, 2019, 11:08 AM EDT) -- WASHINGTON, D.C. — On May 21, the federal government filed an amicus curiae brief recommending that the U.S. Supreme Court deny certiorari to a genetic testing company that was unsuccessful in its petition for inter partes review (IPR) of a competitor’s patent, opining that the Federal Circuit U.S. Court of Appeals ruling at issue did not properly address the presented question regarding patent priority and prior art (Ariosa Diagnostics Inc. v. Illumina Inc., No. 18-109, U.S. Sup.)....